Source comparison
Timing Matters — Morning vs Evening Administration
MK-677 has a 24-hour half-life, meaning plasma concentrations remain elevated throughout the day regardless of administration timing. However, timing does influence side effect profiles and subjective tolerance. Most clinical trials administer MK-677 in the ev
This comparison does not assign a generated winner or score.
- MK-677 has a 24-hour half-life, meaning plasma concentrations remain elevated throughout the day regardless of administration timing. However, timing does influence side effect profiles and subjective tolerance. Most clinical trials administer MK-677 in the evening. Typically 30–60 minutes before sleep. To capitalize on the body's natural nocturnal GH pulse and mitigate daytime appetite stimulation.
- Ghrelin receptor activation increases hunger signaling in the arcuate nucleus, which can be disruptive during waking hours but beneficial during sleep when food intake isn't an option. Evening dosing also aligns with endogenous GH secretion patterns: approximately 70% of daily GH output occurs during deep sleep stages (N3), and MK-677 amplifies this existing pulse rather than creating a flat elevation throughout the day.
- Some research protocols use morning administration when appetite stimulation is the primary endpoint. Studies evaluating MK-677 for cachexia or failure to thrive in elderly populations deliberately dose in the morning to maximize daytime caloric intake. The compound's half-life ensures GH elevation persists regardless, but subjective side effects (lethargy, increased appetite, mild insulin resistance) are timing-dependent. Our team has found that evening dosing produces better adherence in long-term protocols because it separates the appetite surge from typical eating windows.